NERLYNX® (neratinib) tablets is indicated for the treatment of early-stage HER2+ breast cancer following adjuvant trastuzumab-based therapy and metastatic HER2+ breast cancer in combination with capecitabine following two or more prior anti-HER2 based regimens in the metastatic setting. Please see important safety information and full Prescribing Information.